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Abstract
Objectives: To assess the diagnostic performance of HACOR scoring system using bedside variables and to predict failure of 
HFNO in patients with acute hypoxemic respiratory failure (AHRF). 
Material and methods: 150 patients with AHRF who were receiving HFNO were enrolled in this study; to predict HFNO treat-
ment failure. A scoring scale (HACOR score) consisted of Heart rate (beats/minute), acidosis (assessed by pH), consciousness 
(assessed by Glasgow coma score), oxygenation, and respiratory rate. Failure was defined as the need for intubation or death. 
Results: Patients were analyzed according to the success or failure of HFNO. Total 150 patients, of which 100 (66.7%) had a suc-
cessful treatment while 50 (33.3%) failed with such intervention. There was an improvement in HR and RR, and PaO2/FiO2 within 
the first hour (T1) in the success group and these parameters continued to improve even after 24 hours (T2) of HFNO treatment.
Patients with HFNO failure had a higher HACOR score at initiation and after 1, 12, 24 and 48 hours. Before intubation, the highest 
value of the HACOR score was reached in the failure group. At 1 h of HFNO assessment, the area under the receiver operating 
characteristic curve was 0.86, showing good predictive power for failure. We found that HACOR score at a cutoff point > 6 had 
81.2% sensitivity and 91% specificity, 92.5% positive predictive value, and 71.4% negative predictive value with a diagnostic 
accuracy was 85%. Furthermore, the overall diagnostic accuracy exceeded 87% when the HACOR score was assessed at 1, 12, 
24 or 48 h of HFNO. 
Conclusions: The HACOR scale is a clinically useful bedside tool for the prediction of HFNO failure in hypoxemic patients. 
A HACOR score < 6 after 1 hour of HFNO highlights patients with < 85% risk of failure. 
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Introduction
High-flow nasal oxygen (HFNO) is an in-
novative system that allows for delivering 
a high flow of heated and humidified gas up to 
60 L/min-1 and 0.21–1.0 of FiO2 through a special 
nasal cannula [1].
HFNO has been increasingly conducted to 
treat acute hypoxemic respiratory failure (AHRF) 
patients [2]. Recent studies have compared the 
efficacy and outcome of HFNO with conventional 
oxygen therapy in (ICU) settings; indicate that 
HFNO demonstrates beneficial effects in terms of 
better oxygenation, as well as reduction of respi-
ratory rate and dyspnoea, resulting in improving 
patient comfort [2, 3].
Using of HFNO can avoid intubation in 
patients with respiratory failure by temporarily 
supporting ventilation during initial treatment, 
but many subjects failed and ultimately need 
intubation. Patients at risk for HFNO failure may 
benefit from early intubation or close observation. 
There is a limited prediction tool to help clini-
cians to determine clinical outcomes and success 
rate in patients treated with HFNO. 
Duan et al. have derived and validated a scor-
ing system which accurately predicts patients 
that would be at risk of noninvasive (NIV) failure 
such that the clinician can plan for the decision 
to implement invasive mechanical ventilation. In 
a derivation cohort of 449 patients, the authors 
used stepwise multivariable regression analysis 
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to identify variables predicting NIV failure. Each 
of the five parameters identified — heart rate, 
acidosis, consciousness (defined by the Glasgow 
Coma Scale [GCS] score), Oxygenation, and Re-
spiratory rate (HACOR) — was assigned points, 
that added  together  to give an overall HACOR 
score. Hypothesizing that, the combination of 
these bedside variables has the potential to in-
crease the predictive power for the prediction of 
NIV failure [4].
Hence, this study aims to assess a bedside 
scoring system based on five variables easily as-
sessed in the emergency room (the HACOR score: 
heart rate, acidosis, consciousness, oxygenation, 
respiratory rate), to predict failure risk in patients 
with hypoxemic ARF treated with HFNO, the need 
for intubation. Hence the clinician can plan for 
the decision to implement invasive mechanical 
ventilation.
Material and methods
We conducted an observational prospective 
study in a 30-bed respiratory ICU at Assuit Uni-
versity Hospital between January 2018 and Febru-
ary 2020. This study was approved by the Faculty 
of Medicine Ethics Committee, Assiut University. 
All the consecutive patients fulfilling the 
diagnostic criteria of acute hypoxic respiratory 
failure (AHRF) admitted to the ICU [5], and 
treated with HFNO were included after taking 
proper consent.
The inclusion criteria were age > 18 years, 
presence of clinical signs and symptoms of AHRF; 
defined by 1) recent dyspnea with a breathing fre-
quency > 25 breaths/min and/or use of accessory 
muscles of respiration with pulmonary infiltrates 
on chest X-ray; 2) a PaO2/FIO2 of > 300 mm Hg 
recorded during spontaneous oxygen ventilation 
at 15 L/min-1 [5].
Patients who had an underlying chronic 
respiratory disease, who require emergent endo-
tracheal intubation, Inability to protect airway 
(excess secretions, drowsy, or comatose patient), 
severe hemodynamic instability (patient on ino-
tropic or vasopressor support), uncooperative 
patient, facial trauma or burns, facial surgery, 
or facial anatomical abnormality) were excluded 
[6].The demographic data of patients such as age, 
sex, the aetiology of acute respiratory failure, and 
presence of associated comorbid illnesses were 
recorded. The disease severity was calculated 
using the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) score on admission to 
ICU [7]. 
Variables for HACOR score including; [heart 
rate (HR), respiratory rate (RR), consciousness 
(Glasgow Coma Scale (GCS), and arterial blood 
gases parameters collected at baseline during 
spontaneous ventilation with a conventional 
face mask and after 1, 12, 24, and 48 hours of 
initiation of HFNO.
These five variables were used to develop 
a risk-scoring system to predict HFNO failure. Each 
data point is assigned such that the sum represent-
ed the HACOR score. The HACOR score ranged 
between 0 to 25 points; higher score suggest an in-
creased risk of HFNO failure [4]. We recorded the 
duration of HFNO therapy, length ICU and hospital 
stay and survival. Also, associated complications 
of HFNO were identified. Patients were followed 
up until death or hospital discharge.
High flow nasal oxygen settings
Patients who met inclusion criteria were 
treated by HFNO. The HFNO device (Optiflow, 
Fisher & Paykel Healthcare, Auckland, New Zea-
land) was applied through a heated humidifier 
and delivered continuously through large-bore 
bi-nasal prongs. HFNO was initially adminis-
tered with a gas flow rate of 50 Lmin-1 and an 
FiO2 of 1.0 and subsequently adjusted to maintain 
SpO2 of 92% or more. 
The following criteria were used for endotra-
cheal intubation [ETI]:
loss of consciousness; hypotension (e.g, sys-
tolic arterial blood pressure < 90 mmHg or mean 
arterial blood pressure < 65 mm Hg) despite ade-
quate fluid resuscitation, or need for vasopressors; 
or two of the following criteria: frank worsen-
ing of respiratory distress, RR > 40 breaths/min, 
SpO2 ≤ 92% despite an FiO2 of 1.0, and/or pH < 
7.35. Failure was defined by the need for endo-
tracheal intubation [5].
Statistical analysis
Data was collected and analyzed using SPSS 
(Statistical Package for the Social Science, version 
20, IBM, and Armonk, New York). Continuous 
variables were expressed as mean ± SD while 
nominal data was expressed in the form of fre-
quency (percentage).
Chi-squared or Fisher’s exact tests were used 
to determine the significance of differences in the 
observed data. A stepwise multivariate regression 
analysis performed to assess HFNO failure, and 
results presented as odds ratio (OR) with 95% 
confidence interval (CI). Diagnostic accuracy of 
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HACOR scale in the prediction of failed HFNO 
was determined with a ROC curve. Level of con-
fidence was kept at 95% and hence, the P-value 
was significant if < 0.05.
Results
150 patients with acute hypoxemic respi-
ratory failure, who were receiving HFNO, were 
enrolled in the study, out of them 100 (66.7%) 
subjects had successful HFNO while 50 (33.3%) 
patients had failed HFNO. Patient’s clinical data 
were presented in Table 1. There were no signif-
icant differences found in age, sex, and aetiology 
of respiratory failure at the time of admission. 
Patients who failed HFNO had significantly higher 
LDH, APACHE-II and HACOR score. 
Changes of physiological parameters between 
baseline T0 (on the initiation of HFNO), the first 
hour after enrolment (T1) and after 24 hours (T2) 
in nasal oxygen success and failure groups are 
shown in Table 2. 
One hour after the enrolment (T1), HR, and 
RR improved in success group as compared to 
failure group (111 ± 16 vs 120 ± 20 beats/minute, 
29 ± 12 vs 34 ± 14 breath/minute), respectively. 
Improvement was maintained after 24 hours 
of therapy (T2). There was also improvement 
in PaO2/FiO2 after one hour in success group 
(185.58 ± 58.5 vs 155.07 ± 52.7), which was 
maintained after 24 (201.53 ± 66.9 vs 175.6 ± 
63.1) hours of therapy. No difference was found 
in blood pressure and PaCO2. 
A summary of HACOR scores at different 
time point from the initiation of HFNO treatment 
to 48 h of HFNO is shown in Table 3. Patients 
with HFNO failure had a higher HACOR score 
at initiation and after 1, 12, 24 and 48 hr than 
those with success group. Before intubation, the 
highest value of the HACOR score was reached 
in patients with HFNO failure.
As presented in Table 4, the predictors for 
failure of HFNO were HACOR score (odds ratio 
= 4.44, 95% confidence interval = 3.09–8.07; P 
< 0.001) and APACHE-II score (odds ratio = 1.43, 
95% confidence interval = 2.01–5.78; P < 0.001) 
with adjusted R2 was 0.65.
The predictive power of HFNO failure diag-
nosed by HACOR score is summarized in Table 
5. After 1 hr of HFNO assessment, the area un-
der the receiver operating characteristic curve 
was 0.86, showing good predictive power for 
failure. It was noticed that using HACOR score 
at cut off point > 6 had 81.2% sensitivity, 91% 
specificity, 92.5% positive predictive value, and 
71.4% negative predictive value for prediction 
of HFNO failure with a diagnostic accuracy was 
85%. Moreover, the overall diagnostic accuracy 
exceeded 87% when the HACOR score was as-
sessed at 1, 12, 24 or 48 hr of HFNO.






Age [year] 65.89 ± 5.67 66.78 ± 10.54 0.09
Male sex 80 (80%) 30 (60%) 0.009
Smoking status
   Smoker
   Ex-smoker 








Causes of acute respiratory failure
   Community acquired pneumonia
   Pulmonary embolism
   Cardiogenic pulmonary edema










Hypertension [n%] 40 (40%) 15 (30%) 0.32
Diabetes mellitus [n%] 32 (32%) 18 (36%) 0.42
C-reactive protein 26.4 ± 8.7 28.8 ± 12.3 0.321
LDH 442 ± 321 657 ± 432 0.001
APACHE-II score 13.77 ± 3.68 19.78 ± 4.09 0.001
HACOR score 5.56 ± 2.09 7.50 ± 1.11 0.001
Data expressed as frequency (percentage), mean (SD). HFNO — high flow nasal oxygen; LDH — lactate dehydrogenase; APACHE-II — acute physiology and chronic 
health evaluation; HACOR — heart rate, acidosis, consciousness, oxygenation, and respiratory rate
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Initiation of HFNO 4.8 ± 2.3 7.4 ± 3.4 0.001
After 1 hour 2.5 ± 2.2 7.5 ± 3.7 0.001
After 12 hours 2.0 ± 2.1 8.3 ± 4.1 0.001
After 24 hours 1.6 ± 1.7 8.1 ± 4.3 0.001
After 48 hours 1.3 ± 1.4 8.4 ± 4.1 0.001
Intubation — 9.5 ± 4.3 —
HFNO — high flow nasal oxygen; HACOR — heart rate, acidosis, conscious-
ness, oxygenation, and respiratory rate







   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)











   Baseline (T0)
   After one hour (T1)










Data expressed as mean (SD). P value was significant if < 0.05. (T0)  — at initiation of HFNO; SBP — systolic blood pressure; DBP — diastolic blood pressure; PaCO2 
— arterial carbon dioxide tension; FiO2 — fraction of inspired oxygen; GCS — Glasgow Coma Scale
Table 4. Predictors of failure of HFNO
Predictors OR 95% CI P value
APACHE-II 1.43 1.01–3.78 < 0.001
HACOR 4.44 3.09–8.07 < 0.001
LDH 1.21 1.11–2.03 0.324
C- reactive protein 1.01 0.9–1.9 0.541
Variables after 1 hour of HFNO
pH+ ≥ 7.35 2.32 1.3–3.2 0.432
PaO2/FiO2 ≥ 200 2.03 1.2–3.6 0.02
OR — odds ratio; CI — confidence interval; LDH — lactate dehydrogenase; 
APACHE-II — acute physiology and chronic health evaluation; HFNO — high 
flow nasal oxygen; HACOR — heart rate, acidosis, consciousness, oxygenation, 
and respiratory rate
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The mean lengths of ICU and hospital stay 
were significantly higher in HFNO failure in 
comparison to the success group Table 6. In-hos-
pital mortality rate was higher in HFNO failure 
patients compared to success group [12 (24 %) 
vs 3 (3%); p = 0.008] respectively. The only re-
ported complication associated with HFNO was 
gastric distension in 24 (48%) failure patients vs 
10 (10 %) in success groups (p = 0.001; Table 5).
Discussion
HFNO has been gaining traction as an ini-
tial treatment in patients with acute hypoxemic 
respiratory failure. High-flow nasal oxygen was 
associated with an increased degree of comfort, 
a reduction in the severity of dyspnea, and a de-
creased respiratory rate [8]. However, many pa-
tients fail HFNO and ultimately need intubation. 
Early intubation or close observation can benefit 
patients at risk for HFNO failure [9]. Hence, we 
evaluate the diagnostic performance of the HA-
COR score to predict HFNO failure in patients 
with hypoxemic respiratory failure admitted to 
a respiratory ICU to avoid delaying intubation 
and decreased hospital mortality.
This score takes into account heart rate, ac-
idosis, consciousness, oxygenation, and respira-
tory rate. Because the parameters in the HACOR 
score are simple bedside measurements, it can 
serve as a rapid and useful tool for predicting 
HFNO failure. The current study revealed that 
33% of patients ultimately failed HFNO and 
predicting the need for intubation. Moreover, 
we noted that HACOR score at the first hour of 
initiation and a cutoff point of 6 has a sensitiv-
ity of 81% and a specificity of 91%, with a good 
diagnostic accuracy 85%.
In agreement with our results, a study con-
ducted by Duan et al. who assessed the usefulness 
of HACOR scale for prediction of NIV failure in 
patients with acute hypoxemic respiratory failure. 
The authors found that HACOR score of > 5 had 
a higher risk of NIV failure. Thus, recognition 
of high risk patients and early intubation may 
presumably reduce hospital mortality [4]. 
Table 5. Predictive power of HACOR score assessed at 1, 12, 24, and 48 hours in prediction of failed HFNO
Indices 1 h 12 h 24 h 48 h
Cut off point > 6
Sensitivity [%] 81.2 78.2 75.4 75.2
Specificity [%] 91 90 88 88
Positive predictive value [%] 92.5 90.2 91.3 91.1
Negative predictive value [%] 71.4 72.2 70.4 70.2
Diagnostic accuracy [%] 85 84 85 87








HACOR — heart rate, acidosis, consciousness, oxygenation, and respiratory rate; AUC — area under the curve of receiver operating characteristics; CI  — confidence 
interval






Duration of high-flow nasal oxygen treatment [days] 4.1±1.3 3.5 ± 2.5 0.229
Length of ICU stay [days] 4.7 ± 2.22 12.2 ± 3.30 0.001
Length of hospital stay [days] 8.2 ± 3.2 15.1 ± 5.1 0.001
Mortality at day 28 [n %] 3 (3%) 7 (14%) 0.01
In-hospital mortality, n° [%] 3 (3%) 12 (24%) 0.001
Complications associated with HFNO
Gastric distension 10 (10%) 24 (48%) 0.001
Data expressed as mean (SD), frequency (percentage)
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Also, Duan et al. studied a novel and prac-
tical risk-scoring system to predict noninvasive 
ventilation (NIV) failure, using bedside clinical 
variables; 500 chronic obstructive pulmonary 
disease (COPD) patients were enrolled in a deri-
vation cohort. The authors demonstrated that NIV 
failure rate was 18.8%, 18.9% and 8.9% in deriva-
tion, internal-validation and external-validation 
cohorts, respectively. In addition, the HACOR 
score had good diagnostic power for NIV failure 
when it was assessed at 1 hr of NIV initiation [10].
The present study, the overall mortality was 
24% in patients with HFNO failure. Therefore, 
early identification of HFNO failure and intuba-
tion is a promising strategy to improve outcome. 
Recently, in a FLORALI study, a randomized trial 
consisting of 310 patients with acute hypoxemic 
respiratory failure allocated to HFNO and stan-
dard oxygen therapy. The authors noted that intu-
bation and mortality rate was significantly lower 
in the HFNO group than in standard oxygen [11].
The points of strength in this study; we assessed 
the performance of a very useful and a newly devel-
oped score in hypoxemic subjects using HFNO. This 
score has not been previously addressed in High 
flow nasal oxygen aiming to improve the clinical 
management and patient’s outcome. Limitation in 
this study, we didn’t assess mean flow and FIO2 used 
by HFNO in the studied population. 
Conclusions: HACOR is a newly developed 
scoring system which takes into account heart 
rate, acidosis, consciousness, oxygenation, and 
respiratory rate to predict failure of HFNO in 
patients with hypoxemic respiratory failure. The 
score appears to be an effective way of predicting 
HFNO failure. This could be a promising tool for 
the clinician to recognize and detect early failure; 
to ensure that there is no delay in intubation. 
Patients with a higher HACOR score are more 
likely to experience failed HFNO. With a cutoff 
value < 6, the diagnostic accuracy of the HACOR 
scale was high. Thus, the HACOR score has been 
identified as a useful tool to pinpoint patients that 
will benefit from such intervention.
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Figure 1. Accuracy of HACOR score in prediction of failed high flow nasal oxygen
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